CTOs on the Move


 
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.89bio.com
  • 535 Mission Street 14th Floor
    San Francisco, CA USA 94105
  • Phone: 212.520.2765

Executives

Name Title Contact Details

Funding

89bio raised $60M on 10/25/2018
89bio raised $83.8M on 07/14/2020

Similar Companies

Ensoma

At Ensoma, we believe every person, no matter where they are in the world, should have access to innovative technologies that are changing the way we treat disease.

AmacaThera

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.

Terumo Interventional Systems

Terumo Interventional Systems is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wax-it Histology Services

Wax-it Histology Services Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cassava Sciences

Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer`s disease. Our novel science is based on stabilizing – but not removing – a critical protein in the brain.